PimedBio
ABOUT US
About US
We create new treatments
based on cutting-edge approaches.
창업이야기
연혁
리더십
협력사
찾아오시는길
PLATFORM
Platform
We create new treatments
based on cutting-edge approaches.
Platform Technology
PIPELINE
Pipeline
We create new treatments
based on cutting-edge approaches.
OVERVIEW
Oncology
IMMUNOLOGY
PR
PR
We create new treatments
based on cutting-edge approaches.
언론보도
공지사항
IR
CAREER
CAREER
We create new treatments
based on cutting-edge approaches.
Recruitment notice
Join us
KR
EN
About Us
창업이야기
연혁
리더십
협력사
찾아오시는길
Platform
Platform technology
Pipeline
Overview
Oncology
PMB212(Cancer stemness blocking agent)
Inhibitor-drug conjugates: IDC
The 3rd-Generation Immuno-oncology therapeutics
Immunology
PMB702(Novel IBD therapeutics)
PR
언론보도
공지사항
IR
Creer
Recruitment notice
Join Us
Instagram
Twitter
Facebook
PIPELINE
Based on innovative scientific achievements,
Pimedbio's first-in-class drugs
OVERVIEW
Oncology
IMMUNOLOGY
Pipeline
Overview
Overview
혁신적인 신약 후보군: 미충족 의료 수요를 해결하기 위한 도전
Oncology
Programs
Target analysis
& Lead design
Hit·Lead discovery
Candidate discovery
Non-clinical studies
& IND filing
Clinical studies
Cancer stemness
blocking agent
(PMB212)
The 3rd-Generation
Immuno-oncology
therapeutics
Bispecific small
molecule : BSMⅡ
Bispecific small
molecule : BSMⅠ
Inhibitor-drug
conjugates : IDC
Immunology
Programs
Target analysis
& Lead design
Hit·Lead discovery
Candidate discovery
Non-clinical studies
& IND filing
Clinical studies
Novel IBD
therapeutics
(PMB702)